Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Hypertension
Interventions: Booster/ low resource, Medium/Level 1 resource intensity, High/Level 2 resource intensity; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension
Interventions: Hymecromone (H01), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Proteinuria, Hypertension, Type II Diabetes
Interventions: Amiloride, HCTZ; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Hypertension, Insulin Resistance
Interventions: Para-aminohippuric Acid, Angiotensin II, Norepinephrine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 58
States / cities: Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Obesity, Metabolic Syndrome X
Interventions: Metformin, Orlistat, Topiramate, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 40 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity, Hypertension
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Amy Arnold; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Postpartum Period, Pregnancy, Hypertension, Pregnancy Induced
Interventions: Postpartum Visits; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Diseases, Hypertension
Interventions: Computerized CKD Education, Usual Hospital Care; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: losartan potassium / hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions: DELPhI system; Device
Lead sponsor: QuantalX Neuroscience; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio

Conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions: Pioglitazone 30mg, Placebo, Labs; Drug · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Retinal Disease, Glaucoma
Interventions: P200TE, Spectral OCT/SLO; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pre-Pulmonary Atrial Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions: Nurse administered, BP Monitor; Behavioral · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions: Balloon pulmonary angioplasty; Procedure
Lead sponsor: International CTEPH Association; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.1%, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 63
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more

Conditions: Postmenopausal Women
Interventions: soy nuts; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Electronic Health Record, Digital Health
Interventions: Connected-device, Usual care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Portola Valley, California • Santa Clara, California

Conditions: Diabetes, High Blood Pressure, Obesity, Hypertension, Heart Diseases, Stroke, TIA, Osteoarthritis, Cancer
Interventions: Nutrition Education; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Mankato, Minnesota

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 4 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 3
States / cities: Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah

Search by objective public record fields.

Titrated Disease Management for Patients With Hypertension

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Caveolin-1 and Vascular Dysfunction

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Angiotensin 1-7 in Obesity Hypertension

Enhancing Care & Outcomes for Patients During the First Postpartum Year

Interactive Computer-adaptive Chronic Kidney Disease Education Program

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

DELPHI in Subjects at Risk for Stroke and Dementia

Bioenergetic Effect of Pioglitazone in CLD-PH

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Comparison of Two Programs to Improve Blood Pressure Treatment Adherence

International BPA Registry

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Soy Nuts and Cardiovascular Risk in Postmenopausal Women

Virtual Hypertension Management Pilot

Study Title: Food Rx

Clinical and Molecular Studies in Families With Glaucoma and Related Diseases